Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Edderd who wrote (18663)	2/11/1999 11:30:00 AM
From: Little Gorilla	Respond to of 23519

As you must know, placebo effects wear off quickly. Just look at the initial Viagra prescription numbers compared to now.

To: Edderd who wrote (18663)	2/11/1999 1:37:00 PM
From: VLAD	Read Replies (1) \| Respond to of 23519

Edderd, If organic impotence is not the "real" market then why are you invested in Vivus? Who can argue that a pill like Viagra is going to get more prescriptions than MUSE since most are going to be for men looking for enhancement who don't even have ED. In fact, Pfizer estimated that 1/2 their Viagra sales would be for enhancement and for a cure. This argument is besides the point. The real question is whether the organic ED market is big enough to make Vivus a profitable small biotech company if they can get the marketing act together. I think so but in the mean time we watch the paint dry.